Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipid-lowering efficacy and safety of statin therapy;Influência de polimorfismos nos genes PPARA, RXRA, NR1I2 e NR1I3 na eficácia hipolipemiante e na segurança da terapia com estatinas

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 57, Issue 7, 2013, Pages 513-519

  Lima, Luciana Otero ^a   Bruxel, Estela Maria ^b   Hutz, Mara Helena ^c   Van der Sand, Cézar Roberto ^d   Van der Sand, Luiz Carlos ^d   Wagner Ferreira, Maria Elvira ^d   Pires, Renan Canibal ^d   Fiegenbaum, Marilu ^a,b   Almeida, Silvana ^a  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^b Centro Universitário Metodista Do IPA   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d Centro de Diagnóstico Cardiológico   (Brazil)

Author keywords

Hydroxymethylglutaryl CoA reductase inhibitors; Nuclear receptors; Pharmacogenetics; Single nucleotide polymorphisms

Indexed keywords

ATORVASTATIN; CELL RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PREGNANE X RECEPTOR; PYRROLE DERIVATIVE; RETINOID X RECEPTOR ALPHA; SIMVASTATIN; STEROID RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; BLOOD; DYSLIPIDEMIA; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTICHOLESTEREMIC AGENTS; DYSLIPIDEMIAS; FEMALE; GENOTYPE; HEPTANOIC ACIDS; HUMANS; LIPIDS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PPAR ALPHA; PYRROLES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RETINOID X RECEPTOR ALPHA; RISK FACTORS; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84887770728     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302013000700003     Document Type: Article

References (32)

1. Polanczyk C, Ribeiro J. Coronary artery disease in Brazil: contemporary management and future perspectives. Heart. 2009;95(11):870-6.
2. Kostis J. The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease. Cardiovasc Drugs Ther. 2007;21(4):297-309.
3. Kajinami K, Takekoshi N, Brousseau M, Schaefer E. Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis. 2004;177(2):219-34.
4. Pang G, Wang J, Wang Z, Lee C. Predicting potentially functional SNPs in drug-response genes. Pharmacogenomics. 2009;10(4):639-53.
5. Giguère V. Orphan nuclear receptors: from gene to function. Endocr Rev. 1999;20(5):689-725.
6. Mandard S, Müller M, Kersten S. Peroxisome proliferatoractivated receptor alpha target genes. Cell Mol Life Sci. 2004;61(4):393-416.
7. Cai Y, Konishi T, Han G, Campwala K, French S, Wan Y. The role of hepatocyte RXR alpha in xenobiotic-sensing nuclear receptormediated pathways. Eur J Pharm Sci. 2002;15(1):89-96.
8. Moreau A, Vilarem M, Maurel P, Pascussi J. Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol Pharm. 2008 2008;5(1):35-41.
9. Wada T, Gao J, Xie W. PXR and CAR in energy metabolism. Trends Endocrinol Metab. 2009;20(6):273-9.
10. Hamilton-Craig I. Statin-associated myopathy. Med J Aust. 2001;175(9):486-9.
11. Tomlinson B, Chan P, Lan W. How well tolerated are lipid-lowering drugs? Drugs Aging. 2001;18(9):665-83.
12. Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
13. Lahiri D, Nurnberger JJ. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19(19):5444.
14. Vohl M, Lepage P, Gaudet D, Brewer C, Bétard C, Perron P, et al. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res. 2000;41(6):945-52.
15. Vasků V, Bienertová Vasků J, Pávková Goldbergová M, Vasků A. Three retinoid X receptor gene polymorphisms in plaque psoriasis and psoriasis guttata. Dermatology. 2007;214(2):118-24.
16. Maekawa B, Cole T, Seip R, Bylund D. Apolipoprotein E genotyping methods for the clinical laboratory. J Clin Lab Anal. 1995;9(1):63-9.
17. Roff D, Bentzen P. The statistical analysis of mitochondrial DNA polymorphisms: chi 2 and the problem of small samples. Mol Biol Evol. 1989;6(5):539-45.
18. Long J, Williams R, Urbanek M. An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet. 1995;56(3):799-810.
19. Peterson R, Goldman D, Long J. Nucleotide sequence diversity in non-coding regions of ALDH2 as revealed by restriction enzyme and SSCP analysis. Hum Genet. 1999;104(2):177-87.
20. Excoffier L, Laval G, Schneider S. Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online. 2005;1:47-50.
21. Lewontin R. On measures of gametic disequilibrium. Genetics. 1988;120(3):849-52.
22. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81(5):582-7.
23. Kivistö K, Niemi M, Schaeffeler E, Pitkälä K, Tilvis R, Fromm M, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics. 2004;14(8):523-5.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc. 1995;57:289-300.
25. Zhang BXW, Krasowski MD. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics. 2008;9(11):1695-709.
26. Ikeda S, Kurose K, Jinno H, Sai K, Ozawa S, Hasegawa R, et al. Functional analysis of four naturally occurring variants of human constitutive androstane receptor. Mol Genet Metab. 2005;86(1-2):314-9.
27. Sewright K, Clarkson P, Thompson P. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep. 2007;9(5):389-96.
28. Mousa O, Brater D, Sunblad K, Hall S. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther. 2000;67(3):267-74.
29. Watanabe H, Kosuge K, Nishio S, Yamada H, Uchida S, Satoh H, et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci. 2004;76(3):281-92.
30. Neuvonen P, Niemi M, Backman J. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565-81.
31. Chen S, Tsybouleva N, Ballantyne C, Gotto AJ, Marian A. Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics. 2004;14(1):61-71.
32. Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos. 2008;36(1):169-81.